It may be true that “two out of three ain’t bad” - but two pieces of good news and one seriously negative item added up to trouble on Wall Street for Flamel Technologies SA. (BioWorld International)

In a deal that could bring Xenon Pharmaceuticals Inc. $157 million in pre-commercial payments, Novartis Pharma AG agreed to research, develop and commercialize compounds from Xenon's SCD1 drug development program. (BioWorld Today)